RJA
SCMP

Raymond James & Associates’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Raymond James & Associates’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,226
Closed -$224K – 3430
2016
Q3 		$224K Buy
18,226
+1,623
+10% +$19.1K ﹤0.01% 2799
2016
Q2 		$182K Buy
16,603
+1,781
+12% +$19.9K ﹤0.01% 2690
2016
Q1 		$162K Buy
+14,822
New +$187K ﹤0.01% 2628

Other funds holding SCMP

LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return

Raymond James & Associates's SCMP Position: Q4 2016 in Review

Raymond James & Associates sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2016, closing a stake of 18,226 shares — an estimated $224K sold.

Raymond James & Associates first reported a position in SCMP in Q1 2016 and held it in 3 quarters. The position peaked at $224K in Q3 2016. 165 funds tracked by Wall St. Rank hold SCMP as of Q4 2016.

  • Raymond James & Associates reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 18,226 Sucampo Pharmaceuticals, Inc. shares in Q4 2016, an estimated $224K.
  • Raymond James & Associates first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • Raymond James & Associates's Sucampo Pharmaceuticals, Inc. position peaked at $224K in Q3 2016.
  • 165 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.